It
lives
to
cl
se
ONLY APLIGRAF® HAS FDA-REVIEWED RCTs RESULTING IN FDA APPROVAL TO HEAL DFUs AND VLUs
DFU RCT
APLIGRAF HEALED MORE DFUs FASTER
ONLY APLIGRAF® HAS FDA-REVIEWED RCTs RESULTING IN FDA APPROVAL TO HEAL DFUs AND VLUs
LOWER RATES OF OSTEOMYELITIS AND AMPUTATION WITH APLIGRAF®
ONLY APLIGRAF® HAS FDA-REVIEWED RCTs RESULTING IN FDA APPROVAL TO HEAL DFUs AND VLUs
VLU RCT
APLIGRAF HEALED MORE VLUs FASTER
APLIGRAF IS 100% COVERED
References: 1. Apligraf [package insert]. Canton, MA: Organogenesis Inc; 2017. 2. Veves A, et al. Diabetes Care. 2001;24(2):290-295. 3. Data on file. Organogenesis Inc. 4. Food and Drug Administration. https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma. Updated May 16, 2019. Accessed January 6, 2026. 5. Food and Drug Administration. https://www.fda.gov/medical-devices/premarket-approval-pma/pma-clinical-studies. Updated February 17, 2023. Accessed January 6, 2026. 6. Falanga V, et al. Arch Dermatol. 1998;134(3): 293-300. 7. Marston WA, et al. Wound Repair Regen. 2014;22(3):334-340. 8. Treadwell T, et al. Adv Wound Care. 2018;7(3):69-76. 9. Sabolinski ML, et al. J Comp Eff Res. 2018;7(8):797-805. 10. Kirsner RS, et al. Wound Repair Regen. 2015;23(5):737-744. 11. Milstone LM, et al. Wounds. 2000;12(5 suppl A):12A-19A. 12. Falanga V, et al. J Invest Dermatol. 2002;119(3):653-660. 13. Schmid P. Wounds. 2000;12(5 suppl A):4A-11A. 14. Carlson M, et al. Tissue Eng Part A. 2011;17(3-4):487-493. 15. Wojtowicz AM, et al. Wound Rep Regen. 2014;22(2):246-255. 16. Data on file. AP_DR-0004. Organogenesis Inc. 17. Stone RC, et al. Sci Transl Med. 2017;9(371):eaaf8611. 18. Brem H, et al. Surg Technol Int. 2003;11:23-31. 19. Stone RC, et al. Wound Repair Regen. 2020;28(2):164-176.
